pr-inside.com
Print

Cytokinetics to Announce Fourth Quarter Results on February 5, 2013



2013-01-29 22:02:40 -


South San Francisco, CA., January 29, 2013, - Cytokinetics, Incorporated
(Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter
results on Tuesday, February 5, 2013 at 4:00 PM Eastern Time. Following the
announcement, Cytokinetics' senior management will host a conference call at
4:30 PM Eastern Time to discuss operational and financial results and the
company's outlook for the future.

The conference call will be simultaneously webcast and can be accessed in the
Investor Relations section of Cytokinetics' website at www.cytokinetics.com. The
live audio of the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078
(international) and typing in the passcode 92558691.

An archived replay of the webcast will be available via Cytokinetics' website
until February 12, 2013.  The replay will also be available via telephone by
dialing (855) 859-2056 (United States and Canada) or (404) 537-3406
(international) and typing in the passcode 92558691from February 5, 2013 at
5:30 PM Eastern Time until February 12, 2013.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment with tirasemtiv produced potentially clinically relevant
pharmacodynamic effects in Phase II trials. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.

Cytokinetics, Incorporated:
Jodi L. Goldstein
Manager, Corporate Communications and Marketing
(650) 624-3000



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1673990]


Press Information:




Contact Person:


Phone:
email: e-mail




Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.